J&J’s comeback kid Spravato heads for blockbuster status

Johnson & Johnson’s esketamine nasal spray Spravato didn’t look like a sure-fire win after it hit the market in 2019. Despite blazing a new trail as the first psychedelic-based treatment to score an FDA nod, the depression medication got off to a sluggish start, and the company didn’t even report sales figures for the first few years. Times have changed.